4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 10% – Here’s Why

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) was up 10% during mid-day trading on Monday . The company traded as high as $13.15 and last traded at $13.4030. Approximately 182,547 shares changed hands during trading, a decline of 77% from the average daily volume of 783,342 shares. The stock had previously closed at $12.19.

4D Molecular Therapeutics News Roundup

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $36 price target, implying substantial upside from recent trading levels. The firm modestly improved its FY2027 EPS forecast to a loss of $4.34 per share from $4.40, while projecting narrowing losses through FY2030. HC Wainwright analyst estimates
• Positive Sentiment: Other analysts remain constructive: Goldman Sachs reiterated a Buy rating with a $32 target, while the broader analyst consensus is Moderate Buy with an average price target of $29.62. 4D Molecular Therapeutics reaches 12-month high
• Positive Sentiment: FDMT recently reached a new 12-month high, trading well above its 50-day and 200-day moving averages. The stock’s elevated volume and momentum may be attracting additional interest, although its high beta indicates significant volatility. 4D Molecular Therapeutics reaches 12-month high
• Neutral Sentiment: Institutional ownership is reported at 99.27%, with new positions from Bank of America, Man Group, Jupiter Topco and other investors. This signals strong institutional interest, though the reported purchase figures may include data-quality anomalies. Institutional ownership and insider trading
• Negative Sentiment: HC Wainwright reduced its FY2028, FY2029 and FY2030 loss estimates slightly, indicating that FDMT is expected to remain unprofitable for several years. The company also recently reported a quarterly loss of $1.04 per share, missing estimates, despite revenue exceeding expectations.
• Negative Sentiment: Insider Scott Bizily sold shares in multiple transactions totaling roughly $39,567 during August and has reduced his direct holdings by 15.95%. While relatively small, the sales could temper investor sentiment. FDMT insider stock sales

Analysts Set New Price Targets

A number of research firms have weighed in on FDMT. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Friday, July 17th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday. Wall Street Zen cut shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Finally, The Goldman Sachs Group reissued a “buy” rating and set a $32.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, 4D Molecular Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $29.62.

4D Molecular Therapeutics Stock Performance

The company has a debt-to-equity ratio of 0.05, a current ratio of 8.03 and a quick ratio of 8.03. The firm has a market capitalization of $769.56 million, a PE ratio of -5.60 and a beta of 2.73. The company’s fifty day simple moving average is $11.17 and its 200 day simple moving average is $9.97.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The business had revenue of $3.78 million during the quarter, compared to analysts’ expectations of $3.62 million. As a group, equities research analysts expect that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the completion of the transaction, the insider directly owned 942,485 shares in the company, valued at approximately $9,867,817.95. The trade was a 10.85% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Scott Bizily sold 9,810 shares of the business’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $12.00, for a total transaction of $117,720.00. Following the sale, the insider directly owned 8,617 shares in the company, valued at $103,404. The trade was a 53.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 200,496 shares of company stock valued at $2,240,244 over the last quarter. 7.90% of the stock is owned by company insiders.

Institutional Trading of 4D Molecular Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in FDMT. AQR Capital Management LLC bought a new position in 4D Molecular Therapeutics in the 1st quarter worth about $46,000. Millennium Management LLC increased its position in shares of 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock valued at $5,278,000 after buying an additional 213,264 shares during the period. Dynamic Technology Lab Private Ltd bought a new stake in shares of 4D Molecular Therapeutics during the first quarter valued at about $39,000. American Century Companies Inc. lifted its holdings in shares of 4D Molecular Therapeutics by 11.5% in the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock worth $181,000 after buying an additional 5,026 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in shares of 4D Molecular Therapeutics by 11.7% in the second quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock worth $81,000 after buying an additional 2,284 shares in the last quarter. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.